Literature DB >> 3948873

Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin.

B J Bourrie, P Casellas, H E Blythman, F K Jansen.   

Abstract

In recent years, antibody--ricin-A-chain immunotoxins have been investigated as anti-neoplastic agents. To achieve in vivo therapy it is necessary that the immunotoxin remains in circulation at a sufficiently high level for a sufficiently long time to allow binding to tumor cells to occur. Therefore, examination of the pharmacology of immunotoxins may elucidate the reasons for the poor in vivo tumoricidal effect of immunotoxin described before. In this study the plasma clearance of antibody--ricin-A-chain immunotoxins, after intravenous injection in animals of different species, has been examined. Sensitive and reproducible techniques were developed to monitor the level of immunotoxin and its constituents in the blood. It is shown that immunotoxins are rapidly eliminated from the bloodstream. Neither the properties of the antibody moiety nor the nature of the linkage binding ricin A-chain to antibody account for the disappearance of immunotoxin from the plasma. On the other hand, we found that the rapid clearance of immunotoxin is due to the mannose residues on the ricin A-chain moiety which are specifically recognized by liver cells. When immunotoxin is administrated together with yeast mannan, which enhances the level of active immunotoxin in circulation by inhibition of liver uptake, the anti-cancer efficacy of immunotoxin in vivo is drastically improved.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3948873     DOI: 10.1111/j.1432-1033.1986.tb09451.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  22 in total

Review 1.  Monoclonal antibodies. Future potential in cancer chemotherapy.

Authors:  C Kosmas; H Kalofonos; A A Epenetos
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 2.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 3.  Therapeutic strategies with monoclonal antibodies and immunoconjugates.

Authors:  V S Byers; R W Baldwin
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

4.  Gene induction by interferons and double-stranded RNA: selective inhibition by 2-aminopurine.

Authors:  R K Tiwari; J Kusari; R Kumar; G C Sen
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

5.  An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys.

Authors:  A A Hertler; D M Schlossman; M J Borowitz; D G Poplack; A E Frankel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.

Authors:  L G Durrant; V S Byers; P J Scannon; R Rodvien; K Grant; R A Robins; R A Marksman; R W Baldwin
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

7.  Gene induction by interferons: functional complementation between trans-acting factors induced by alpha interferon and gamma interferon.

Authors:  S K Bandyopadhyay; D V Kalvakolanu; G C Sen
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

Review 8.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

9.  Production of a human monoclonal antibody recognising a determinant on mouse IgG2b from a patient receiving mouse monoclonal antibody for diagnostic imaging.

Authors:  L G Durrant; R A Robins; K C Ballantyne; E B Austin; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

10.  Endocytosis of ricin by rat liver cells in vivo and in vitro is mainly mediated by mannose receptors on sinusoidal endothelial cells.

Authors:  S Magnússon; T Berg
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.